Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Journal: Dermatologic Surgery : Official Publication For American Society For Dermatologic Surgery [Et Al.]
Published:
Abstract
Background: Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.
Objective: To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.
Results: After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor.
Conclusions: Imiquimod 5% cream may be another treatment modality for nodular BCC.
Authors
Amy Huber, John Huber, Robert Skinner, Raymond Kuwahara, Raashid Haque, Rex Amonette
Relevant Conditions